BioCentury | Nov 12, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-10b (miR-10b)

...studies suggest an miR-10b inhibitor plus doxorubicin could help treat metastatic breast cancer. Levels of miR-10b...
...with non-metastatic breast cancer, respectively. In human metastatic cancer cell lines, nanoparticles loaded with an anti-miR-10b...
...Inc. has an anti-miR-10b antisense oligonucleotide in preclinical testing to treat brain cancer. TARGET/MARKER/PATHWAY: MicroRNA-10b (miR-10b...
BioCentury | Aug 20, 2012
Finance

Ducks in a row

...is partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Regulus has at least one unpartnered compound targeting miR-10b...
BioCentury | Apr 8, 2010
Targets & Mechanisms

miRNA inhibition of metastasis

...of targeting miR-10b . Studies carried out over the past five years have shown that miR-10b...
...of miR-10b did not block the growth of existing metastases. "This suggests that inhibition of miR-10b...
...said. Regulus holds an issued patent covering the use of the anti-miR-10b antagomir and other anti-miR-10b...
BioCentury | Apr 5, 2010
Clinical News

Regulus preclinical data

...pulmonary breast cancer metastases by 86% compared with saline-treated controls (p=0.00005). The antisense oligonucleotide targeting microRNA-10b...
...antagomir (p=0.00004). Data were published in Nature Biotechnology. Regulus Therapeutics Inc. , Carlsbad, Calif. Product: Anti-miR-10b...
BioCentury | Apr 1, 2010
Distillery Therapeutics

Indication: Cancer

...antagonizing miR-10b could help prevent breast cancer metastasis. In mice, an anti-miRNA oligonucleotide (antagomir) against miR-10b...
Items per page:
1 - 5 of 5